Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T Cells Targeting MAGE-A4 in Advanced Mesenchymal Malignancies
NCT07467122Phase 1Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in sarcoma, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Number of participants with treatment-related Grade >=3 cytokine release syndrome (CRS) or neurotoxicity at 7 days, Number of participants with treatment-related Grade >=3 non-hematologic adverse events at 28 days and 1 more. Started Mar 2026; status: recruiting.
02
Conditions
sarcoma
Beyond the preview
Go deeper on NCT07467122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07467122.